Antivirus solution: According to the guidelines[16 ,18 (link)], the 309 patients were treated by experienced clinicians at or above the attending level with the following regimen: (1) Sofosbuvir 400 mg/d + daclatasvir 60 mg/d + ribavirin 1000 mg/d (12 wk) regimen (95 cases); (2) sofosbuvir 400 mg/d+ Velpatasvir 100 mg/d (12 wk) (60 cases); (3) sofosbuvir 400 mg/d+ ribavirin 1000 mg/d (12 wk) (57 cases); (4) Ombitasvir 300 mg/d+ dasabuvir 500 mg/d (12 wk) (44 cases); (5) sofosbuvir 400 mg/d+ ledipasvir 90 mg/d+ ribavirin 1000 mg/d (12 wk) regimen (22 cases); (6) Elbasvir and Grazoprevir 50 mg/d (12 wk) (17 cases); and (7) Dasabuvir 60 mg+ Asunaprevir 100 mg (24 wk) regimen (14 cases).
Non-antiviral treatment: Inclusion reasons: (1) Because some patients could not choose pegylated interferon (peg-IFN) + ribavirin due to decompensation of cirrhosis, and DAA drugs were not released in China before 2017; and (2) Some patients cannot choose the treatment due to the economic burden.
Patients without antiviral treatment were received the corresponding hepatoprotective treatment and symptomatic treatment.